TORONTO -- A vaccine designed to prevent dementia is ready to enter the human trial stage within two years after successful tests on mice, researchers say.
The study, published in the journal 鈥溾�� explores the 20 years of U.S.-backed research that was mostly carried out at South Australia鈥檚 Flinders University by Nikolai Petrovsky.
The treatment consists of a combination of two drugs that target and remove 鈥渂rain plaque鈥� and tau protein aggregate that are linked to the neurodegeneration and cognitive decline exhibited in Alzheimer鈥檚 disease, .
Petrovsky told Australia鈥檚 The Daily Telegraph , that 鈥渢his vaccine could be revolutionary,鈥� but warned that it would be a while before it was available to the general public.
The release states that Alzheimer鈥檚 disease is the leading cause of age-related dementia and affects approximately 5.7 million people in the U.S., and that many other promising drugs have previously failed in clinical trials.
